ALK and lung adenocarcinoma: We found that PD-L1 and HLA-I expression were adverse predictors of ALK rearrangement in lung adenocarcinomas, and that the abundance of CD8+ TILs in ALK-positive tumors was not different from that in ALK-negative tumors.